(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/260120 A1

(51) International Patent Classification:
A61K 31/4545 (2006.01) *A61P 25/00* (2006.01)
A61K 45/06 (2006.01) *A61P 43/00* (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:
PCT/EP2021/067366

(22) International Filing Date:
24 June 2021 (24.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20182067.7 24 June 2020 (24.06.2020) EP

(71) Applicant: **ORPHAZYME A/S** [DK/DK]; c/o COBIS A/S Ole Maaløes Vej 3, 2200 Copenhagen N (DK).

(72) Inventors: **JENSEN, Thomas, Kirkegaard**; Rønneholmsvej 37, 2610 Rødovre (DK). **HINSBY, Anders, Mørkeberg**; Sømarksvej 4, 2900 Hellerup (DK). **FOG-TØNNESEN, Cathrine, Kolster**; Peder Godskes Vej 11, 2830 Virum (DK). **INGEMANN, Linda**; Ved Renden 13, 2870 Dyssegård (DK). **Í DALI, Christine**; Rigensgade 9b, st., 1316 Copenhagen K (DK).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2021/260120 A1

(54) Title: ARIMOCLOMOL FOR TREATING GAUCHER DISEASE

(57) Abstract: The present invention relates to an active pharmaceutical ingredient selected from N- [2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof; specifically arimoclomol, for use in methods of treating Gaucher disease (GD).